Loading
A phase 3 trial of Trastuzumab deruxtecan, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations is a phase 3 interventional study registered as NCT05048797 by AstraZeneca, with 454 participants enrolled, started 2021-10-28 and due to reach its primary completion in 2026-06-09. Interventions recorded: Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed. Conditions listed: Locally Advanced or Metastatic Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads).
Shares Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin, Carboplatin.
Shares Pemetrexed, AstraZeneca, Cisplatin, Carboplatin.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Cisplatin.
Shares HER2-mutant non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, AstraZeneca, Carboplatin, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/